Progyny, Inc. (PGNY)
Market Cap | 1.84B |
Revenue (ttm) | 1.17B |
Net Income (ttm) | 54.34M |
Shares Out | 85.41M |
EPS (ttm) | 0.57 |
PE Ratio | 37.70 |
Forward PE | 13.52 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,004,619 |
Open | 22.08 |
Previous Close | 22.05 |
Day's Range | 21.49 - 22.14 |
52-Week Range | 13.39 - 38.98 |
Beta | 1.42 |
Analysts | Buy |
Price Target | 21.83 (+1.56%) |
Earnings Date | May 8, 2025 |
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s... [Read more]
Financial Performance
In 2024, Progyny's revenue was $1.17 billion, an increase of 7.22% compared to the previous year's $1.09 billion. Earnings were $54.34 million, a decrease of -12.41%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PGNY stock is "Buy." The 12-month stock price forecast is $21.83, which is an increase of 1.56% from the latest price.
News

Progyny Expands Family Building Solutions with New Parent and Child Well-being Offering
The in-demand program provides high-touch, holistic support for working parents and caregivers, addressing return-to-work challenges, emotional health support, and benefit navigation The in-demand pro...

Progyny, Inc. to Participate in Upcoming Investor Conferences
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced it expects to participate ...
PGNY CEO on "Well-Positioned" Sales Year & Expanding Footprint
Pete Anevski, CEO of Progyny (PGNY), discusses his company's latest earnings and how it's poised for a "well-positioned" year. He notes general healthcare headwinds for the women's health company, tho...

Progyny, Inc. (PGNY) Q4 2024 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY) Q4 2024 Earnings Conference Call February 27, 2025 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Mark Livingston -...

Progyny, Inc. Announces Fourth Quarter 2024 Results
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Rev...

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results Report
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the q...

Kuehn Law Encourages Investors of Progyny, Inc. to Contact Law Firm
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY) breached their f...

Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump
Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning Provides expecting parents with a concierge-level serv...

Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year h...

Securities Fraud Investigation Into Progyny, Inc. (PGNY) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Progyny, Inc. (“Progyny” ...

Progyny, Inc. (PGNY) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Progyny, Inc. (“Progyny” or the “Company”) (NASDAQ: PGNY) investors concerning the Company's poss...

Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services
BLOOMFIELD, Conn. , Jan. 13, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasda...

The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with...

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...

PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated sec...

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclo...

Four hidden gems in the stock market from a five-star fund manager
Investors might be well served by expanding beyond the S&P 500.

Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated ...

Progyny: Rating Downgrade On Uncertain Growth Outlook
I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins fallin...

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, a...

Progyny, Inc. to Present at Jefferies London Healthcare Conference
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny'...

These Analysts Slash Their Forecasts On Progyny Following Q3 Results
Progyny, Inc. PGNY reported worse-than-expected third-quarter sales results and issued FY24 revenue guidance below estimates.

Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
Progyny, Inc (NASDAQ:PGNY) Q3 2024 Earnings Conference Call November 12, 2024 4:45 PM ET Company Participants James Hart - Investor Relations Peter Anevski - CEO Michael Sturmer - President Mark Livi...

Progyny, Inc. Announces Third Quarter 2024 Results
Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Ser...

Progyny (PGNY) Client Retention Narrative Under Examination - Hagens Berman
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fertility benefits provider Progyny, Inc. (NASDAQ: PGNY) is under intense scrutiny following the unexpected announcement of a major client's departure.